Cipla Q4 profit misses estimates as US market competition weighs

Cipla, India’s third-largest drugmaker by revenue, reported weaker-than-expected fourth-quarter earnings on Wednesday as weak sales and intense competition in its key US market weighed on performance.

The company’s consolidated net profit fell 54.6% year-on-year to 5.55 billion rupees ($58 million) for the quarter ended March 31.

The earnings figure came in below analysts’ average estimate of 7.05 billion rupees, according to data compiled by LSEG.

US market weakness impacts earnings

Cipla’s quarterly performance was affected by softer sales in the United States, which remains one of the company’s most important markets.

The company also faced stiff competition in the region, which pressured revenue and profitability during the quarter.

The decline in earnings reflected the challenging operating environment for the drugmaker in the US market, where pricing pressure and competition continued to impact business performance.

Profit drops more than half year-on-year

The company’s consolidated net profit dropped significantly compared with the same quarter a year earlier.

Cipla reported a profit of 5.55 billion rupees in the March quarter, marking a 54.6% decline from the previous year.

The result also fell short of market expectations tracked by LSEG analysts.

The weaker earnings performance highlighted the pressure on the company’s core business operations during the quarter.

Analysts estimates missed

According to data compiled by LSEG, analysts had expected Cipla to report an average quarterly profit of 7.05 billion rupees.

However, the company’s actual reported figure came in substantially lower than estimates.

The earnings miss reflected weaker-than-anticipated sales performance and competitive pressure in the US market.

Cipla remains India’s third-largest drugmaker by revenue, but the latest quarterly results underscored the challenges facing pharmaceutical companies operating in highly competitive global markets.

Cipla’s Q3 sales highlight strength

Meanwhile, Cipla reported steady operational performance in its unaudited consolidated financial results for the quarter ended December 31, 2025, despite pressure from declining sales.

The company posted global revenue of 7,074 crore rupees during Q3 FY26, while EBITDA stood at 1,255 crore rupees with margins at 18%.

Profit after tax came in at 676 crore rupees.

The branded prescription segment reported double-digit growth, led by respiratory, urology, cardiac, and anti-diabetes therapies.

Cipla added that Foracort retained its position as the top-ranked brand in the Indian pharmaceutical market, according to IQVIA MAT December 2025 data.

The trade generics business also recorded healthy growth, driven by distribution expansion, new product launches, and technological interventions.

During the quarter, the company launched eight new products, including an entry into the sexual wellness category.

Cipla’s consumer health business maintained leadership positions through brands such as Nicotex, Omnigel, and Cipladine, while continuing to expand distribution channels.

The company also highlighted its upcoming respiratory pipeline for FY27, including gAdvair and gVictoza, along with three additional peptide assets expected to launch during the fiscal year.